Antimicrobial peptides as a promising treatment option against Acinetobacter baumannii infections

Neshani, Alireza; Sedighian, Hamid; Mirhosseini, Seyed Ali; Ghazvini, Kiarash; Zare, Hosna; Jahangiri, Abolfazl

doi:10.1016/j.micpath.2020.104238

Cited by 63 publications

(37 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This successful nosocomial pathogen is considered by the Infectious Diseases Society of America (IDSA) as one of the six most dangerous microbes 3 . High mortality rate (more than 70%) 4 and difficulty in the clinical management of A. baumannii-associated infections are attributed to the emergence of highly antibiotic-resistant strains [5][6][7] . These implications motivated researchers to introduce efficient antibiotics against this notorious pathogen.…”

mentioning

confidence: 99%

Specific egg yolk immunoglobulin as a promising non-antibiotic biotherapeutic product against Acinetobacter baumannii pneumonia infection

Jahangiri

Owlia

Rasooli

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

Acinetobacter baumannii is a serious health threat with a high mortality rate. We have already reported prophylactic effects of IgYs raised against OmpA and Omp34 as well as against inactivated whole-cell (IWC) of A. baumannii in a murine pneumonia model. However, the infection was exacerbated in the mice group that received IgYs raised against the combination of OmpA and Omp34. The current study was conducted to propose reasons for the observed antibody-dependent enhancement (ADE) in addition to the therapeutic effect of specific IgYs in the murine pneumonia model. This phenomenon was hypothetically attributed to topologically inaccessible similar epitopes of OmpA and Omp34 sharing similarity with peptides of mice proteins. In silico analyses revealed that some inaccessible peptides of OmpA shared similarity with peptides of Omp34 and Mus musculus. Specific anti-OmpA and anti-Omp34 IgYs cross-reacted with Omp34 and OmpA respectively. Specific IgYs showed different protectivity against A. baumannii AbI101 in the murine pneumonia model. IgYs triggered against OmpA or IWC of A. baumannii were the most protective antibodies. IgY triggered against Omp34 is ranked next after those against OmpA. The lowest protection was observed in mice received IgYs raised against the combination of rOmpA and rOmp34. In conclusion, specific IgYs against OmpA, Omp34, and IWC of A. baumannii could serve as novel biotherapeutics against A. baumannii pneumonia.

show abstract

mentioning

confidence: 99%

Specific egg yolk immunoglobulin as a promising non-antibiotic biotherapeutic product against Acinetobacter baumannii pneumonia infection

Jahangiri

Owlia

Rasooli

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…During the recent COVID-19 pandemic, the widespread use of broad-spectrum antimicrobials and corticosteroids to treat patients, the use of mechanical ventilation and prolonged hospitalization might increase the risk for MDR pathogen infection. Antimicrobial peptides (AMPs) have antimicrobial mechanisms different from pre-existing small molecule antibiotics; hence, they can effectively eliminate MDR pathogens and become potential alternatives to combat superbugs (Hancock and Sahl, 2006;Deslouches et al, 2013;Feng et al, 2013;Mahlapuu et al, 2016;Lei et al, 2019;Mohan et al, 2019;Raheem and Straus, 2019;Magana et al, 2020;Neshani et al, 2020;Upert et al, 2020). Colistin, a peptide antibiotic against Gram-negative bacteria, was discovered in the 1940s.…”

Section: Introductionmentioning

confidence: 99%

“…As an opportunistic pathogen, it is one of the leading causes of nosocomial infections worldwide (Almasaudi, 2018). Recently, several designed peptides have shown promising efficiency in eliminating A. baumannii in mice (Neshani et al, 2020). An in silico designed 20-mer peptide, named 76, showed high efficacy against carbapenem-and tigecyclineresistant A. baumannii in a mouse intraperitoneal infection model (Nagarajan et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

A Systematic Study of the Stability, Safety, and Efficacy of the de novo Designed Antimicrobial Peptide PepD2 and Its Modified Derivatives Against Acinetobacter baumannii

Chen

Yang

et al. 2021

Front. Microbiol.

View full text Add to dashboard Cite

Searching for new antimicrobials is a pressing issue to conquer the emergence of multidrug-resistant (MDR) bacteria and fungi. Antimicrobial peptides (AMPs) usually have antimicrobial mechanisms different from those of traditional antibiotics and bring new hope in the discovery of new antimicrobials. In addition to antimicrobial activity, stability and target selectivity are important concerns to decide whether an antimicrobial peptide can be applied in vivo. Here, we used a simple de novo designed peptide, pepD2, which contains only three kinds of amino acid residues (W, K, L), as an example to evaluate how the residues and modifications affect the antimicrobial activity against Acinetobacter baumannii, stability in plasma, and toxicity to human HEK293 cells. We found that pepI2 with a Leu→Ile substitution can decrease the minimum bactericidal concentrations (MBC) against A. baumannii by one half (4 μg/mL). A D-form peptide, pepdD2, in which the D-enantiomers replaced the L-enantiomers of the Lys(K) and Leu(L) residues, extended the peptide half-life in plasma by more than 12-fold. PepD3 is 3-residue shorter than pepD2. Decreasing peptide length did not affect antimicrobial activity but increased the IC50 to HEK293 cells, thus increased the selectivity index (SI) between A. baumannii and HEK293 cells from 4.7 to 8.5. The chain length increase of the N-terminal acyl group and the Lys→Arg substitution greatly enhanced the hemolytic activity, hence those modifications are not good for clinical application. Unlike colistin, the action mechanism of our peptides relies on negatively charged lipids rather than lipopolysaccharides. Therefore, not only gram-negative bacteria but also gram-positive bacteria can be killed by our peptides.

show abstract

“…Al-Khafaji and Farah T. Al-Alaq Department of Biology, College of Science, University of Babylon, Hilla, Iraq *Address all correspondence to: dr.dahmoshi83@gmail.com Omega76, AM-CATH36, Hymenochirin, and Mastoparan were suitaple AMPs and have the highest anti-A. baumannii [83][84][85].…”

Section: Author Detailsmentioning

confidence: 99%

Virulence and Antibiotic Resistance of Acinetobacter baumannii among Urinary Tract Infections

Al-Dahmoshi¹,

Al-Khafaji²,

Al-Alaq³

2022

Urinary Tract Infection and Nephropathy - Insights Into Potential Relationship

View full text Add to dashboard Cite

Acinetobacter baumannii is one of the opportunistic bacteria firstly related with the hospital acquired infection influencing primarily to weakening the patient in the ICU. It is sometimes transferred to the patient by transient colonization of hands of the workers of healthcare, and persistence on eco-surfaces. Acinetobacter baumannii inhalation aerosolized through endo-tracheal suctioning of the ventilated patient is widespread among ventilator-related pneumonia (VAP). It is infections mainly associated with ventilator-related pneumonia (VAP), community Acquired Pneumonia (CAP), invasive bacterial infections (IBIs) and UTI (urinary tract infection). It is one of the prominent uropathogens problematic with antibiotic resistance especially carbapenem resistant Acinetobacter baumannii (CRAB). Their colonization of urinary tract and establishment of infection may attributed mainly to set of virulence factors like: Acinetobactin-assisted iron acquisition system, Bap (biofilm-related protein), phospholipase D, Ata (Acinetobacter trimeric autotransporter), chaperone-usher type pilus (Csu), OmpA (outer membrane protein A), and Plasminogen-binding protein (CipA). The common drugs used for treatment Acinetobacter baumannii infections involve polymyxins, glycylcyclines, tetracyclines, mono-bactams, fluoroquinolones, aminoglycosides, antipseudomonal carbapenems, antipseudomonal cephalosporins, and sulbactam. The rates of MDR isolation or also comprehensively the resistant Acinetobacter baumannii are significantly increased and so the combination of two or more (colistin, tigecycline, or colistin-rifampicin combination therapy) drugs is sometimes used to treat infections of MDR-AB. As a conclusion the Acinetobacter baumannii engagement in urinary tract infections attributed mainly to their adhesins, invasins and intrinsic antibiotic resistance.

show abstract

Antimicrobial peptides as a promising treatment option against Acinetobacter baumannii infections

Cited by 63 publications

References 139 publications

Specific egg yolk immunoglobulin as a promising non-antibiotic biotherapeutic product against Acinetobacter baumannii pneumonia infection

Specific egg yolk immunoglobulin as a promising non-antibiotic biotherapeutic product against Acinetobacter baumannii pneumonia infection

A Systematic Study of the Stability, Safety, and Efficacy of the de novo Designed Antimicrobial Peptide PepD2 and Its Modified Derivatives Against Acinetobacter baumannii

Virulence and Antibiotic Resistance of Acinetobacter baumannii among Urinary Tract Infections

Contact Info

Product

Resources

About